MP-AzeFlu Is More Effective Than Fluticasone Propionate for the Treatment of Allergic Rhinitis in Children

W Berger, J Bousquet, A T Fox, J Just, A Muraro, A Nieto, E Valovirta, M Wickman, U Wahn

Allergy. 2016 Aug;71(8):1219-22.

PMID: 27043452

Abstract:

The objective was to evaluate the efficacy of MP-AzeFlu (Dymista(®) ) vs fluticasone propionate (FP), (both 1 spray/nostril bid), in children with allergic rhinitis (AR). MP-AzeFlu combines azelastine hydrochloride, FP and a novel formulation in a single spray. Children were randomized in a 3 : 1 ratio to MP-AzeFlu or FP in this open-label, 3-month study. Efficacy was assessed in children aged ≥ 6 to <12 years (MP-AzeFlu: n = 264; FP: n = 89), using a 4-point symptom severity rating scale from 0 to 3 (0 = no symptoms; 3 = severe symptoms). Over the 3-month period, MP-AzeFlu-treated children experienced significantly greater symptom relief than FP-treated children (Diff: -0.14; 95% CI: -0.28, -0.01; P = 0.04), noted from the first day (particularly the first 7 days) and sustained for 90 days. More MP-AzeFlu children achieved symptom-free or mild symptom severity status, and did so up to 16 days faster than FP. MP-AzeFlu provides significantly greater, more rapid and clinically relevant symptom relief than FP in children with AR.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP78957854	A3 hydrochloride		78957-85-4	Price